23andme

Toolbox Genomics, a company that will soon begin to offer actionable health insights based on customers' sequenced genomes, has raised a small round of seed funding, the company told MobiHealthNews.

Almost two years after the FDA first told 23andMe to halt sales on its mail-order direct-to-consumer genetic testing service for disease risks, the company has relaunched a version of its new Personal Genome Service (PGS), which now meets FDA standards.

Mail-order personal genetics service and research company 23andMe has completed a $115 million in a round led by Fidelity Management and Research Company with participation from  Casdin Capital, WuXi Healthcare Ventures, and Xfund, as well as existing investors Illumina, New Enterprise Associates, MPM Capital, and Google Ventures.

Practice Fusion's Ryan Howard (right) and MobiHealthNews' Jonah Comstock at Health 2.

Ancestry.

According to an SEC filing, mail-order personal genome service and research company 23andMe has raised $79 million, in a round the company hopes will top out at $150 million.

San Francisco-based video visits company Doctor On Demand raised $50 million in a round led by Tenaya Capital with participation from new investors Qualcomm Ventures, Dignity Health, and 23andMe CEO Anne Wojcicki.

Jawbone's UP2 device Some 20 percent of investors said they expect Jawbone to go public this year, according to a Rock Health survey of 43 investors.

Google-backed 23andMe is finally relaunching its mail-order personal genome service -- just not in the United States.

Google's genomics browser, from a video the company released last year.